Not so long ago, research protocols excluded older cancer patients based on chronologic age. Now they exclude patients with comorbidities, and as most older patients suffer additional ailments, they do not fit the protocols. But [more]
For most of us, sooner or later, old age will bring frailty and chronic health conditions, making the task of living the life we wish progressively harder. We will want oncologists who know what different [more]
Delaying treatment for a curable prostate cancer is an increasingly popular option among men with low risk tumours. Simon Crompton looks at efforts to learn more about who benefits and how to avoid delaying too [more]
Prioritising collaboration over self-interest is the way to learn about who gets the best from which treatments in the complex world of advanced prostate cancer. Silke Gillessen talked to Simon Crompton about how she is [more]
It makes no sense to perform clinical research that has no relevance to patient care, so why do we do it, and how can we stop? John Ioannidis ponders the problem and offers some suggestions. [more]
The state of the art on the diagnosis and management of cancer of the pancreas and hepatobiliary system was the focus of the 3rd St Gallen Gastrointestinal Cancer Conference, held earlier this year under the [more]
P Hadji, R E. Coleman, C Wilson et al. (2016) Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol 2016, 27:379–90 Bisphosphonates should be considered as part [more]
Cancer has traditionally been the diagnosis people fear most. But is dying from cancer so much worse than the alternatives? Anna Wagstaff tries to make sense of an emotive discussion that all started with a [more]
Treatment of advanced-stage ovarian cancer should comprise optimal debulking surgery followed by adjuvant intraperitoneal chemotherapy. Steven Narod, from Women’s College Research Institute, Toronto, Canada, argues that widespread adoption of this model would increase cure rates [more]
Despite a rapid rise in cancer cases in low- and middle-income countries, many governments have been disastrously slow to turn their attention to planning and implementing cancer services, thanks in no small part to the [more]
Tomosynthesis carries a great promise in improving cancer detection and reducing the number of false positives. As yet its drawbacks are: higher and longer radiation exposure, longer compression time and therefore longer lasting pain and [more]
For patients with localized prostate cancer (PCa), active surveillance might not be easy to deal with, with possible repercussions on the quality of life: starting from this åassumption, the European School of Oncology convened a [more]
Rare cancers make up as many as one fifth of all new cancer cases. Amongst them, pediatric cancers and rare hematologic neoplasms are often covered by dedicated educational events, while adult solid rare cancers are [more]